Among hypercortisolemia pharmacotherapy, GR antagonists (mifepristone) or modulators (miricorilant) seem to have the most divergent liver safety profile reports, which can mainly be explained by dose dependence and the rate of LS reduction. The gene discussed is NR3C1; the disease is adrenal gland hyperfunction.